Replacing PEG with PCB in lipid nanoparticles led to potent mRNA vaccines that avoided unwanted immune responses.

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential ...

Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). Survival ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and ...

Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

The global lipid nanoparticles market is on the cusp of remarkable expansion, projected to grow at a CAGR of 14% through 2035, according to a recent industry analysis. Estimated to generate USD 1,144.

LNP that are used today for mRNA therapies are up to 200,000-250,000 times more active than those that were originally developed for small interfering RNA therapies. In addition, the LNP has also ...

mRNA vaccines offer clear advantages and disadvantages ... “In addition, advances in delivery technologies over current gold-standard LNP approaches to improve immunogenicity and reduce dosing ...

A new drug delivery system developed by researchers at the University of Hawaiʻi at Mānoa John A. Burns School of Medicine ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...